. home.aspx



Novo Nordisk’s Victoza gets FDA okay for paediatric use

June 18, 2019 / Phil Taylor

Novo Nordisk’s GLP-1 agonist Victoza has become the first non-insulin drug to be approved in the US as a treatment for type 2 diabetes in children for almost two decades. The FDA says the okay to use Victoza (liraglutide) in paediatric patients aged 10 or over comes “at a time when an increasing number of children are being diagnosed with this disease.” The last drug to be approved for paediatric use in type 2 diabetes was metformin back in 2000. Type 2 diabetes is typically first diagnosed in people aged over 45, with the type 1, autoimmune form of the disease the most likely to be encountered in children. Latterly however, rising levels of overweight and obesity in even very young children has caused an uptick in type 2 cases in this age group. The US Centers for Disease Control and Prevention estimates that more than 5,000 new cases of type 2 diabetes are diagnosed each year among in people younger than age 20 in the US, out of around 1.4 million new cases across a...